Avastin® (bevacizumab) is given as an infusion. That means you get Avastin through a small needle in your vein or through a port, which is a device placed under your skin.
Because Avastin is given as an infusion, infusion-related reactions may occur. Avastin infusions will be stopped by your doctor or nurse if infusion reactions are severe.
Your doctor or nurse will monitor you for signs of an infusion-related reaction, which may include:
Avastin infusions are given every 2 or 3 weeks to treat your metastatic colorectal cancer. Because Avastin can be scheduled on the same day you get your IV 5-FU-based chemotherapy, it may not require extra visits to an infusion center.
Avastin is given every 2 weeks for metastatic colorectal cancer (mCRC) patients starting Avastin for first- or second-line treatment.
Avastin is given every 3 weeks for metastatic colorectal cancer (mCRC) patients continuing on Avastin for second-line treatment after a first-line treatment containing bevacizumab.
You always get the same dose of Avastin. If your Avastin infusions are tolerated, they can take as little as 30 minutes.
Your doctor or nurse will monitor you for signs of infusion-related reactions, and may stop Avastin treatment if severe reactions occur. Reactions can include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, serious allergic reactions, chest pain, headache, tremors, and excessive sweating.
Questions about Avastin treatment costs? Let us help you understand your financial assistance options.
Avastin is a tumor-starving therapy. Read more about how it's designed to work.
Find helpful information and support.
Avastin is approved to treat metastatic colorectal cancer (mCRC) for:
Avastin is not approved for use after surgery was used as the primary treatment in patients with colon cancer which has not spread to other parts of the body.
Avastin, in combination with carboplatin and paclitaxel, is approved to treat advanced nonsquamous non–small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.
Avastin is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).
Avastin, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).
Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.
Avastin, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.
Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (prOC) in women who received no more than two prior chemotherapy treatments.
Avastin, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (psOC).
Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Everyone reacts differently to Avastin therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.
In clinical studies across different types of cancer, some patients experienced the following side effects:
Talk to your doctor if you are:
For more information about your treatment or condition, talk to your doctor.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see full Product Information for additional important safety information.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.